---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-022062"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:51:45.390822+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Celcuity expands debt to $75M, Q2 net loss $10M, gedatolisib gets Breakthrough Therapy

## Summary
- Debt facility amended to up to $75M ($50M increase); $15M drawn, $20M due on private placement close; other tranches tied to clinical milestones.
- Q2 2022 net loss $10.0M ($0.67 loss per share) vs $14.0M ($1.11) in Q2 2021; non-GAAP adjusted loss $8.3M ($0.55).
- FDA granted Breakthrough Therapy designation in July for gedatolisib in HR+/HER2- metastatic breast cancer.
- Private placement of $100M equity signed May 2022; closing expected after first patient dosed in VIKTORIA-1.
- VIKTORIA-1 Phase 3 trial on track to dose first patient shortly; FACT-1/2 interim data expected mid-2023.

## SEC filing metadata
- accession: 0001493152-22-022062
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 2.02, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/0001493152-22-022062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000149315222022062/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-022062
- JSON: https://secwatch.observer/filing/0001493152-22-022062.json
- Plain text: https://secwatch.observer/filing/0001493152-22-022062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.